Implantable Device Deliver Drugs Directly To Tumors To Limit Side Effects

Implantable Device Deliver Drugs Directly To Tumors To Limit Side Effects
Researchers at the University of North Carolina at Chapel Hill have revealed that an implantable device can deliver a toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them - all while showing signs that the rest of the body would be spared toxic side effects.
 
The work, published in the Proceedings of the National Academy of Sciences, highlights the cocktail FOLFIRINOX, a combination of four chemotherapy drugs that has been shown to shrink tumors or halt their growth in nearly a third of pancreatic cancer patients. It's one of today's first-line treatments for pancreatic cancer, but it is not suitable for all patients due to its degree of toxicity when delivered through the bloodstream. The new device, currently tested in mice, delivers the drugs directly to the tumor, providing a viable alternative to sending this toxic cocktail through the bloodstream, limiting harsh effects throughout the rest of the body.
 
Surgically removing a tumor is currently the best chance of cure for patients with pancreatic cancer, but only 15 percent of patients have operable tumors. The new device could potentially help more patients qualify for surgery.
 
The findings are the latest for the researchers in the testing of the implantable device, which uses electric fields to drive the chemotherapy drugs directly into tumors. In a study published last year in Science Translational Medicine, the team showed, for the first time in animal models, that the device could be implanted on top of pancreatic tumors to increase the amount of the cancer drug gemcitabine reaching them. The tumors stopped growing and shrunk, providing more favorable conditions to remove the tumor and cure the disease.
 
The discovery was hailed as a big advance for the treatment of pancreatic cancer, which has a 75 percent mortality rate within a year of diagnosis - a statistic that has not changed in more than 40 years.
 
The latest study builds on last year's critical advance. Like the previous study, the device increased the amount of drug reaching the tumors, lowered drug concentration in the blood and significantly impacted tumor growth compared to intravenous delivery of the same drugs. But this time, the device was used with a more potent four-drug combination, making the treatment more effective while limiting unbearable side effects. The accumulation of drug in the tumor using the device was at least three times greater than when using IV administration.
 
"The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body," said James D. Byrne, the paper's first author. "If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments."
 
If you appreciate our work, consider making a contribution